Sirolimus 0.2%

DRUG2 trials

Sponsors

Aucta Pharmaceuticals, Inc, Narrows Institute for Biomedical Research

Conditions

Acanthosis NigricansAngiofibroma of FaceTuberous Sclerosis

Phase 2

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

TerminatedNCT03363763

Aucta Pharmaceuticals, IncAngiofibroma of Face, Tuberous Sclerosis

Start: 2017-04-12End: 2023-03-24Updated: 2025-12-01

Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans

CompletedNCT06940895

Narrows Institute for Biomedical ResearchAcanthosis Nigricans

Start: 2025-03-01End: 2025-07-18Updated: 2025-11-28